SNCA and Parkinson disease: We further achieve an ultrasensitive immunoassay for a Parkinson’s disease biomarker, alpha-synuclein (α-syn), with a lower LOD of 0.32 pM in serum, which is three orders of magnitude lower than the α-syn concentration in the serum of Parkinson’s disease patients.